- Home >
- Publications >
- Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Authors
William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Abstract
Abstract
Background
In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.
Methods
Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease. CTC with a
Results
In 154 screened patients, ≥ 1 and ≥ 5 CTC/7.5 ml of blood were detected in
Conclusions
CTC with